Q3 Earnings Estimate for Organovo Issued By Zacks Small Cap

Organovo Holdings, Inc. (NASDAQ:ONVO) – Equities researchers at Zacks Small Cap upped their Q3 2025 EPS estimates for Organovo in a report issued on Monday, November 11th. Zacks Small Cap analyst B. Sorensen now anticipates that the medical research company will post earnings per share of ($0.21) for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Organovo’s current full-year earnings is ($0.77) per share. Zacks Small Cap also issued estimates for Organovo’s Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.77) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.75) EPS.

Separately, StockNews.com started coverage on shares of Organovo in a research note on Monday. They set a “sell” rating on the stock.

Organovo Price Performance

NASDAQ:ONVO opened at $0.36 on Wednesday. The company has a market cap of $5.53 million, a P/E ratio of -0.33 and a beta of 0.62. Organovo has a fifty-two week low of $0.35 and a fifty-two week high of $1.74. The firm’s 50 day moving average is $0.47 and its two-hundred day moving average is $0.67.

Hedge Funds Weigh In On Organovo

A hedge fund recently bought a new stake in Organovo stock. Armistice Capital LLC bought a new stake in Organovo Holdings, Inc. (NASDAQ:ONVO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned 6.46% of Organovo at the end of the most recent quarter. 8.23% of the stock is currently owned by institutional investors.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.